Bioprocess

CELLINK launches the S.NEST, a high-throughput microbioreactor with real-time monitoring to ensure maximum cell growth and streamlined workflows

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Articles, Biological engineering, Technology, Computer architecture, Cellink, Bioprocess, Bioreactor, Cell

STOCKHOLM, July 19, 2021 /PRNewswire/ --CYTENA Bioprocess Solutions, a CELLINK company, has launched the S.NEST, a state-of-the art microbioreactor that maximizes cell growth while monitoring and analyzing cell conditions from start to finish.

Key Points: 
  • STOCKHOLM, July 19, 2021 /PRNewswire/ --CYTENA Bioprocess Solutions, a CELLINK company, has launched the S.NEST, a state-of-the art microbioreactor that maximizes cell growth while monitoring and analyzing cell conditions from start to finish.
  • Well-known for combining innovative bioscience technologies with best-in-class software development, CYTENA Bioprocess Solutions has developed their new microbioreactor to disrupt the field of cell line development (CLD).
  • As part of CYTENA's extensive portfolio of single-cell instruments, the S.NEST will make highly efficient cell culturing results accessible to laboratories around the world.
  • "The S.NEST revolutionizes cell culturing workflows with its unique technology to increase efficiency and productivity for biologics production, drug screening and functional genomics," says Charles Tsai, PhD, CEO CYTENA Bioprocess Solutions.

CASTL Named Exclusive Provider of Global Organization’s Biopharmaceutical Training Program for Canada

Retrieved on: 
Tuesday, July 13, 2021
Research, Biotechnology, Other Health, Other Education, Training, Health, Other Science, Science, Education, Biotechnology, Articles, Bioprocess, Center for Advanced Study in Theoretical Linguistics, Center for Chemistry at the Space-Time Limit, Natural sciences, Academic disciplines, CASTL, NIBRT, CASTL, NIBRT

View the full release here: https://www.businesswire.com/news/home/20210713005152/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210713005152/en/
    The Canadian Alliance for Skills and Training in Life Sciences (CASTL) has been named the exclusive provider of a global organizations biopharmaceutical training program for Canada.
  • A global centre of excellence for training and research in bioprocessing, the National Institute for Bioprocessing Research and Training (NIBRT) develops state-of-the-art training and education programs for academic institutions and the worlds leading biopharmaceutical manufacturing companies.
  • We are thrilled to be the exclusive provider of NIBRTs best-in-class training in Canada to support our growing bioscience industry, said Penny Walsh-McGuire, Executive Director, CASTL.
  • NIBRTs Global Partner Programme supports an international alliance of leading training and education organizations to help address the global shortage of a skilled biopharmaceutical manufacturing workforce.

$348.9 Million Continuous Bioprocessing Markets, 2028 by Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D) & End User (Pharmaceuticals, Biotechnology, CROs) - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Chemicals, Plastics, Natural Resources, Other Natural Resources, Manufacturing, Life sciences, Biotechnology, Articles, Biology, Bioprocess, Biopharmaceutical, Compound annual growth rate, Monoclonal antibody, Pharmaceutical industry in India

The "Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global continuous bioprocessing market is expected to grow at a CAGR of 23.0% from 2020 to 2027 to reach $348.9 million by 2027.
  • Some of the major factors driving this market's growth include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals.
  • Based on end user, the CDMOs and CROs segment is expected to grow at the highest CAGR during the forecast period.

Demeetra AgBio Advances Major Pipeline for Therapeutic Cannabinoid Development; Invites Collaborations

Retrieved on: 
Wednesday, June 16, 2021
Branches of biology, Biology, Life sciences, Medicinal plants, Entheogens, Euphoriants, Biotechnology, Herbalism, Cannabinoid, Cannabis, Bioprocess, Medical cannabis

In a recent CRISPR Medicine News feature , Demeetra CEO Jack Crawford says, "many of the 120+ cannabinoids already produced naturally in cannabis [are] not produced at levels sufficient for R&D and commercial manufacturing.

Key Points: 
  • In a recent CRISPR Medicine News feature , Demeetra CEO Jack Crawford says, "many of the 120+ cannabinoids already produced naturally in cannabis [are] not produced at levels sufficient for R&D and commercial manufacturing.
  • Demeetra is leveraging its precision gene editing tools in combination with traditional breeding techniques to manufacture specialized plants and other bioprocessing systems that produce targeted therapeutic cannabinoids.
  • Demeetra is also developing processes to manufacture biotherapeutics at scale, using yeast and Chinese hamster ovary (CHO) cell lines as bioprocess platforms.
  • Demeetra is advancing a pipeline of therapeutic cannabinoids and plans to file an IND in Q1 of 2022 for its lead candidate.

Demeetra AgBio Advances Major Pipeline for Therapeutic Cannabinoid Development; Invites Collaborations

Retrieved on: 
Wednesday, June 16, 2021
Biotechnology, Bioprocess, Chinese hamster ovary cell, Tissue plasminogen activator

There are also significant opportunities to enhance natural cannabinoids for therapeutic purposes by using gene editing in combination with synthetic biotechnology...we are working towards building a platform of virtually unlimited bioproduct candidates."

Key Points: 
  • There are also significant opportunities to enhance natural cannabinoids for therapeutic purposes by using gene editing in combination with synthetic biotechnology...we are working towards building a platform of virtually unlimited bioproduct candidates."
  • Demeetra is leveraging its precision gene editing tools in combination with traditional breeding techniques to manufacture specialized plants and other bioprocessing systems that produce targeted therapeutic cannabinoids.
  • Demeetra is also developing processes to manufacture biotherapeutics at scale, using yeast and Chinese hamster ovary (CHO) cell lines as bioprocess platforms.
  • Demeetra is advancing a pipeline of therapeutic cannabinoids and plans to file an IND in Q1 of 2022 for its lead candidate.

Codiak BioSciences Expands Executive Leadership

Retrieved on: 
Tuesday, June 15, 2021
Biotechnology, Bioprocess, Freeze-drying, Boston, Geography of Massachusetts, Matter, Articles

I am delighted to work alongside these long-time colleagues as we chart the path for Codiak's next phase of growth.

Key Points: 
  • I am delighted to work alongside these long-time colleagues as we chart the path for Codiak's next phase of growth.
  • Dr. Konstantinov most recently held the position of Executive Vice President, Manufacturing and Process Sciences.
  • Before joining Codiak in January 2016, he was responsible for the late-stage bioprocess and technology development at Sanofis Boston hub, including all functions from cell banking to fill/finish/lyophilization.
  • All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.

Global Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Analysis by Technology, Cell Type, End User, and Geography - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 2, 2021
Health, Biotechnology, Biotechnology, Life sciences, Articles, Bioprocess, Biopharmaceutical

The "Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Cell Type, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Cell Type, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global cell therapy bioprocessing market is expected to reach US$ 30,052.61 million in 2028 from US$ 11,192.50 million in 2020.
  • Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing).
  • Such instances of investments are expected to boost the sector and enhance the cell therapy bioprocessing in the coming future.

GPB Scientific Announces Additional Growth Financing to Support Commercialization of Curate™ Cell Processing System for Next-Generation Cell & Gene Therapies

Retrieved on: 
Thursday, May 27, 2021
Research, FDA, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Branches of biology, T cells, Clinical medicine, Biotechnology, Immune system, Medicine, Bioprocess, Chimeric antigen receptor T cell, TRA, GBP Scientific, Vensana Capital, Amgen Ventures, GBP SCIENTIFIC, VENSANA CAPITAL, AMGEN VENTURES

This financing will support expanded placements of GPBs Curate Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as well as development of the platforms utility in additional types of cell and gene therapy applications.

Key Points: 
  • This financing will support expanded placements of GPBs Curate Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as well as development of the platforms utility in additional types of cell and gene therapy applications.
  • The Curate system utilizes GPBs proprietary Deterministic Cell Separation technology to deliver unmatched recovery, purity, and cell health impacting each of these challenges in bioprocessing for cell and gene therapies.
  • He commented, "The Curate system is poised to be transformative for cell and gene therapies.
  • GPB Scientific is a pioneering biomedical company realizing the promise of its Curate Cell Processing System.

Qosina Partners with Nordson MEDICAL to Support Single-Use Bioprocess Integrators and Medical Device Manufacturers

Retrieved on: 
Tuesday, May 25, 2021
Research, Medical devices, Medical Supplies, Chemicals, Plastics, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Cuyahoga County, Ohio, Nordson Corporation, Bioprocess, Articles, Original equipment manufacturer, Medical device, Business, Economy

Qosina is pleased to announce that it has entered into a distribution agreement with Nordson MEDICAL, a premier manufacturer and supplier of components to the bioprocess and medical device industries.

Key Points: 
  • Qosina is pleased to announce that it has entered into a distribution agreement with Nordson MEDICAL, a premier manufacturer and supplier of components to the bioprocess and medical device industries.
  • Nordson MEDICAL customers who wish to purchase lower quantities of medical device and bioprocess components may place these types of orders directly with Qosina at www.qosina.com .
  • Qosina has been a trusted supplier of OEM components to the medical device and pharmaceutical industries for more than 40 years, and is an integral part of the supply chain.
  • Founded in 1980, Qosina is a leading global supplier of OEM single-use components to the medical and pharmaceutical industries.

Global Biofuels, Waste Management, Brine Recycling, and Cell Culturing Innovations Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021
Environment, Articles, Energy, Nature, Biotechnology, Sustainable technologies, Bioenergy, Alternative energy, Renewable energy, Bioprocess, Biomass, Alternative fuel, Bioplastic

b'The "Growth Opportunities in Biofuels, Waste Management, Brine Recycling, and Cell Culturing" report has been added to ResearchAndMarkets.com\'s offering.\nThis edition of the Industrial Bioprocessing Technology Opportunity Engine (TOE) features information on the use of unique carbon dioxide capture technology to reduce emissions in the construction industry, utilization of cost-effective distillation and pyrolysis technologies for plastics and end-of-life tire management.\nThe TOE also features information on the use of breakthrough technology based on temperature swing solvent extraction for efficient brine recycling in the desalination process.\nThe TOE also focuses on innovations associated with the cost-effective conversion of biomass into biocoal and also provides insights on the use of photocatalysts for the conversion of plant biomass into valuable products.\nThe TOE additionally provides insights on the latest developments in the algae production systems for the development of Spirulina-based dietary supplements, the latest trends in the use of cell culturing for developing healthier meat and milk supplements, and the use of renewable diesel and bio-plastics that can effectively replace fossil fuels.\nThe Industrial Bioprocessing TOE provides intelligence on technologies, processes and strategic insights of industries involving bioprocessing, including innovations in the development and production of chemicals, pharmaceuticals, nutraceuticals, alternative fuels, chemical feedstocks, food and beverages, and consumer products.\n'

Key Points: 
  • b'The "Growth Opportunities in Biofuels, Waste Management, Brine Recycling, and Cell Culturing" report has been added to ResearchAndMarkets.com\'s offering.\nThis edition of the Industrial Bioprocessing Technology Opportunity Engine (TOE) features information on the use of unique carbon dioxide capture technology to reduce emissions in the construction industry, utilization of cost-effective distillation and pyrolysis technologies for plastics and end-of-life tire management.\nThe TOE also features information on the use of breakthrough technology based on temperature swing solvent extraction for efficient brine recycling in the desalination process.\nThe TOE also focuses on innovations associated with the cost-effective conversion of biomass into biocoal and also provides insights on the use of photocatalysts for the conversion of plant biomass into valuable products.\nThe TOE additionally provides insights on the latest developments in the algae production systems for the development of Spirulina-based dietary supplements, the latest trends in the use of cell culturing for developing healthier meat and milk supplements, and the use of renewable diesel and bio-plastics that can effectively replace fossil fuels.\nThe Industrial Bioprocessing TOE provides intelligence on technologies, processes and strategic insights of industries involving bioprocessing, including innovations in the development and production of chemicals, pharmaceuticals, nutraceuticals, alternative fuels, chemical feedstocks, food and beverages, and consumer products.\n'